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INTERLEtrKIN-I levels are elevated in inflammatory bowel
disease. In this study the mechanism by which
interleukin-l affects electrolyte transport in the rabbit
distal colon, was investigated. Interleukin-l caused a
delayed increase in short-circuit current (Isc) which was
attributed to protein synthesis since the effect was inhib-
ited by cycloheximide. The interleukin-l induced in-
crease in Isc was not affected by amiloride treatment but
was completely inhibited by bumetanide or in chloride-
free buffer and by indomethacin. Prostaglandin E levels
increased in tissue treated with interleukin-l, but this
increase was reversed by cycloheximide. These data sug-
gest that interleukin-l causes its effect via a yet to be
identified second messenger, by increasing chloride se-
cretion through a prostaglandin E mediated mechanism.
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Introduction
IL-1 is a cytokine of around 17 kDa which is
responsible for mediating a variety of processes in
host defence, inflammation, and response to injury.
It is produced by diverse cell types following infec-
tion or injury. On the basis of several overlapping
activities and similar patterns of production, IL-1 may
be grouped with tumour necrosis factor- (TNF0t,
and IL-6 as factors mediating common effects. 2,3 It is
produced by a variety of cells such as fibroblasts and
T and B lymphocytes and consists of two distinct but
related molecules, IL-10t and IL-I[ which are en-
coded by separate genes; in most human tissues IL-
1[3 mRNA predominates over IL-10t mRNA. Both
forms appear to function by binding to the same
membrane-associated receptor. IL-1 appears to be a
primary molecule in inflammatory reactions through
its induction of other inflammatory metabolites, e.g.
it induces production of prostaglandin E (POE2) and
phospholipase a (PEA2).
In the intestine, increased IL-1 production has
been reported in the mucosa of patients with inflam-
matory bowel disease and in intestinal tissue of
animal models of colitisTM suggesting that IL-1 may
be involved in the pathophysiology of inflammatory
bowel disease. IL-1 has been shown to stimulate el:
and HCO3- secretion in the chicken intestine12 and
inhibit Na and C1- absorption in rabbit ileum,1
however, the role and mechanism of action of IL-1 in
affecting secretory function in the normal colon has
not been fully elucidated.
More than one second messenger seems to be
involved in mediating the effects of IL-1. Some of
these mediators include nitric oxide (NO), cAMP and
phospholipases C and A2 .14’15 In this study, the actions
( 1995 Rapid Communications of Oxford ktd
of IL-113 on electrolyte transport in normal rabbit
distal colon and the second messenger(s) that might
be involved in its mechanism of action are character-
ized. It was also determined whether TNF0t has
similar effects to IL-1 on ion transport in the rabbit
colon since, although TNFz and IL-1 are biochemi-
cally distinct cytokines, they have many related and
overlapping biological functions, and they play im-
portant and similar roles in many immune re-
sponses.
2,
Materials and Methods
Human recombinant IL-1[3, atropine, tetrodotoxin,
indomethacin, amiloride, NG-l-nitro+arginine me-
thyl ester (NAME), bumetanide, cycloheximide,
actinomycin D and human recombinant TNFz were
obtained from Sigma (St Louis, MO). For some ex-
periments IL-113 was obtained as a gift from Drs P.
Smith and J. Lee at Smith Kline and Beecham (Phila-
delphia, PA).
Transport studies: Male New Zealand albino rabbits
weighing 2-3 kg were maintained on a standard
rabbit chow diet with free access to water. The
animals were killed by an overdose of pentobarbital
sodium (i.v.). The distal colon was removed and
epithelial sheets devoid of serosa and muscularis
propria were prepared for transport studies. Colonic
mucosa was mounted as a fiat sheet between two
Lucite modified Ussing chambers having an aperture
of 1.13 cm2, and oxygenated and maintained at 37C.
Short-circuit current (Isc) which is equivalent to the
electrical sum of all ion transport processes occurring
simultaneously was determined. An automatic volt-
age clamp (W.P.I., Sarasota, FL), corrected for fluid
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resistance between the potential difference sensing
bridges, provided continuous short-circuiting of the
tissue.
Unless specified, the bathing solution consisted of
Krebs-HCO (KBS) composed of (in mM): KC1 4.8,
CaCl2 2.5, NaC1 118.1, NaH2PO 1.2, MgSO 1.2,
NaHCO3 25, glucose 11, pH 7.4 after gassing with
95% 02/5% CO2. Human recombinant IL-I[ was used
in this study. It has previously been shown that rabbit
and human IL-1 cross-react with an antibody to
human IL-116 and that rabbit and human IL-1 have
approximately 65% homology.
17 Amiloride and
bumetanide were dissolved in 100% ethanol and
indomethacin dissolved in 10 mM sodium carbonate.
All reagents were added to the serosal bathing solu-
tion. Ion substitution studies were performed by
either replacing Cl- ions by gluconate ions or replac-
ing HCO= ions by HEPES solution.
Measurement ofPGEe levels in tissue treated with IL-
lfJ: Stripped distal colon mucosal sheets were
washed with KBS, placed on ice and cut into small
but equal pieces. For all assays, pieces of tissue were
transferred to polypropylene vials containing 5 ml of
oxygenated KBS at 37C in a slow shaking water
bath. The tissue was continuously oxygenated dur-
ing the experiment. Aliquots were transferred from
the supernatant to Eppendorf tubes at specific times
and centrifuged at 4C, for 2 min at 7 000 g in the
Eppendorf centrifuge. Samples were kept at-70C
for later determination of PGE levels using
radioimmunoassay (RIA). Commercially available
RIA kits for measurement of PGE2 were used (Ad-
vanced Magnetics Inc., MA). The sample was precipi-
tated with cold acetone, centrifuged and the precipi-
tate discarded. Petroleum ether was then added to
the supernatant and the aqueous phase separated
and acidified to pH 3-4 and then extracted further
with ethyl acetate. The sample was lyophilized and
reconstituted in a known amount of assay buffer. In
brief, the assay involved incubating the sample with
the corresponding antiserum overnight at 4C and
then centrifuging for 15 min at 4C at 1 000 x g. The
supernatant was then transferred to scintillation vials,
scintillant was added and the vial counted in a liquid
scintillation counter.
Statistical analyses: Statistical analyses were per-
formed with Student’s t-test for paired and unpaired
data; half-maximal and maximal effects of IL-I[ on
transport were determined by the method of
Woolf-Hanes
18 by plotting the concentration/change
in Isc vs. concentration. In these calculations, the half-
maximal concentration and the maximal effect for
each experiment were determined, and the results
are presented as the means of these + S.E. Unless
specified all results are reported as mean + S.E.
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Results
Effects ofIL-l on Isc in rabbit distal colon: IL-1 (0.1
to 10 ng/ml) was added to the serosal bathing solu-
tion and Isc monitored for 60 min. IL-I[ caused a
significant, concentration dependent increase in Isc
(Fig. 1A) with an EC50 of 0.2 ng/ml. The peak increase
in Isc was 24.1 + 2.5 A/cm (basal Isc was 79.0 + 13.5
btA/cm2) and was reached 40-50 min after the addi-
tion of IL-I[. This increase however was delayed and
only observed 10-20 min after the addition of IL-11
(Fig. 1B).
Effects ifIL-l on Isc in thepresence ofindomethacin,
atropine and TTX: To determine the mechanism by
which IL-I[ causes its effects on electrolyte transport,
the colonic tissue was treated with either
indomethacin (1 M), a cyclooxygenase inhibitor
which prevents the production of prostaglandins,
atropine (1 l.tM), a cholinergic inhibitor, or TTX (1
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FIG. 1. (A) Concentration-dependent response of the effect of IL-I on
rabbit colonic short circuit current (n 6). IL-1 was added to the serosal
surface of’the tissue, and the data based on the maximum increase in
short-circuit current is shown for each concentration tested. A separate
piece of stripped distal colon was used for each determination. (B) The
effect of IL-I on short-circuit current as a function of time from a single
representative experiment.Regulation of ion transport by IL-I
btM), a neuronal Na channel inhibitor which pre-
vents neural input to the epithelial cells. IL-13 (1 ng/
ml) was added to the serosal side of the colon in the
Ussing chamber after pretreating the tissue with ei-
ther of these inhibitors and the peak change in Isc was
measured. Indomethacin decreased the Isc by 7.3 +
2.1 A/cm2. It completely abolished the effects of IL-
1[3 on Isc (% Alsc caused by IL-lJ3 in the presence of
indomethacin was-10.2 + 13.2 ILtA/cm2, Fig. 2) sug-
gesting that IL-113 mediates most of its effects through
the production of prostaglandins.
Atropine alone had no effect on Isc and had no
effect on IL-l-induced increases in Isc. TTX, which
alone caused a decrease in Isc of 8.2 + 0.7 a/cm2,
inhibited the, effect of IL-1[3 by 56 + 17% (Fig. 2)
indicating that while there is a large portion of the
effect being mediated through enteric nerves, there
is a possibility of a direct effect exerted on epithelial
cells.
The nature of the ion involved in IL-1 effect: To
determine the nature of the ion(s) whose transport is
affected by IL-1 treatment, treatment of the tissue
with amiloride, bumetanide or ion substitution stud-
ies were performed. Chloride ion was substituted for
g|uconate to determine if it is involved in the action
of the cytokine. Amiloride, at 1 btM, an inhibitor of
the apical Na channel, had no effect on the IL-l[3
induced increase in Isc (14.3 + 1.2 La/cm in control
tissue vs. 14.3 + 0.9 A/cm in tissue treated with
amiloride, n 3,p > 0.1, NS), suggesting that Na ion
movement is not affected, while C1- replacement
completely reversed the increase in Isc (Fig. 3).
Bumetanide (10 laM), an inhibitor of the Na+/K+/2Cl
transporter present on the basolateral membranes of
the crypt cells, had no effect on Isc alone, also caused
complete inhibition of the effect of IL-lJ3 on Isc (16 +
i lLtA/cm in control tissues vs. 0 + 2 tA/cm in
bumetanide treated tissue, n 5, p < 0.005; and -9
+ 3 btA/cm in chloride-free buffer, n 5, p < 0.001).
From these data we conclude that IL-1[3 causes a
significant increase in anion secretion, mainly CI-,
which causes the increase in Isc observed in the
Ussing chamber.
The effect ofIL-l on theproduction ofPGE2" Treat-
ment of stripped tissue with IL-1]3 (1 ng/ml) caused
a significant increase in the production of PGE (Fig.
4) compared with a time control (5 + I ng/mg protein
in control tissue vs. 12 + 2 ng/mg protein in treated
tissue, n 6, p < 0.05). The time course for PGE
production followed a similar course to the effect
observed on Isc in Fig. lb. The levels of LTB were
undetectable in control and in IL-l-treated tissues.
Effects oflL-l in thepresence ofcycloheximide and
actinomycin D: To test if protein synthesis is the
reason for the delayed effect observed for the action
of IL-I, the tissue was treated with cycloheximide
(100 l.tg/ml), a protein synthesis inhibitor, or with
actinomycin D (10 g/ml), a transcription inhibitor.
As shown in Fig. 5, the effect of IL-113 on Isc was
significantly inhibited when the tissue was treated
with cycloheximide on the serosal side for 15 min
prior to the addition of the cytokine. The IL-I[3-
induced increase in Isc in the presence of
cycloheximide was 2.3 + 1.2 [.ta/cm vs. the effect of
IL-113 alone, 16.3 + 5.0 A/cm (n 5, p < 0.001).
Actinomycin D also caused an inhibition but this was
not complete (Fig. 5). The IL-1]3-induced increase in
Isc in the presence of actinomycin D was 4.8 + 2.8 btA/
cm vs. the effect of IL-I alone, 16.4 + 3.1 A/cm (n
5, p < 0.01). This is attributed to the short time of
incubation (2 h) with the inhibitor since the tissue’s
conductance started to decrease after 3-4 h of
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FIG. 2. The effect of IL-113 on short-circuit current alone and after incubating
the tissue with l.tM indomethacin (indo), l.tM atropine and tM TTX. The
data (mean +/- S.E., n 6, *p < 0.05, p value represents the comparison of
the IL-1 on short-circuit current in the presence of the inhibitor to its effect
alone) are presented as percentage change in short-circuit current caused
by IL-113.
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FIG. 3. The effect of IL-113 on short-circuit current alone and in the presence
of chloride-free buffer or bumetanide (10 lLtM)..The data (mean +/- S.E., n
6, *p < 0.05. p value represents the comparison of the IL-1 on short-circuit
current in the presence of the inhibitor to its effect alone) are presented as
change in short-circuit current caused by IL-113.
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mounting in the Ussing chambers. Neither
cycloheximide nor actinomycin D had any effect on
Isc when added alone. In all these experiments, Br-
cAMP (100 l.tM) was added at the end of the experi-
ment to test if either of the treatments (cycloheximide
or actinomycin D) were toxic to the tissue. Br-cAMP
caused a rapid increase in Isc of 29.0 + 5.7 [t.ta/cm in
control tissue compared with 29.0 + 0.9 [tA/cm (p >
0.1, NS, n 5) in tissue treated with cycloheximide
and. 21.8 + 3.2}.tA/cm in tissue treated with
actinomycin D (p > 0.1, NS; n 5). These data suggest
that indeed protein synthesis is involved in the effect
of IL-113 on ion transport and would explain the
delayed effect observed in Isc.
The effect ofIL-I on the production ofPGE2 in the
presence of cycloheximide: Cycloheximide (100 btg/
ml) significantly inhibited the increase in PGE ob-
served in tissue treated with IL-1I (Fig. 6). This
suggests that IL-1[ causes an increase in protein
synthesis whose function is to increase the produc-
tion of PGE which in turn causes an increase in C1-
secretion. Cycloheximide had no significant effect on
PGE, production in control untreated tissue.
The effect of IL-I in the presence of nitric oxide
synthase (NOS) inhibitor: To test if NO is mediating
the effects of IL-1 in the rabbit distal colon, NG-nitro-
t-arginine methyl ester (NAME) at different concen-
trations (0.5-5 Mm) was added to the serosal surface
of the tissue and the effect of IL-I[ on Ic was tested.
The increase in I caused by IL-1[ was not affected
by NAME added either at the same time with the IL-
11 or 20 min before (Isc 11.5 + 1.3 a/cm in control
tissue vs. 9.2 + 1.8 btA/cm in tissue pretreated with
NAME (0.5 mM) for 20 min prior to IL-1 addition, vs.
8.2 + 2.1 A/cm in tissue treated with NAME and IL-
1[ simultaneously, n 5; p > 0.1; NS). Similar results
were obtained with the different concentrations of
NAME. used (data not shown).
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FIG. 4. The effect of IL-I on the production of PGE (,) as a function of
time, compared with a time control (O). Each point represents mean +/- S.E.,
n 6, *p < 0.05.
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FIG. 5. The effect of IL-11 on short-circuit current alone and in the presence
of cycloheximide (CYX, 100 lg/ml), actinomycin D (ACD, 10 lg/ml) and
NAME (500 M). The data (mean +/- S.E., n 5, *p < 0.05. p value
represents the comparison of the IL-1 on short-circuit current in the pres-
ence of the inhibitor to its effect alone) are presented as percentage change
in short-circuit current caused by IL-I.
The effect of TNFc on Isc in rabbit distal colon: We
found no evidence in the rabbit colon for a similar
action of TNF to that observed by IL-1. TNF at
different concentrations (0.1-100 ng/ml) added to
the serosal bathing solution, had no effect on Ic
(TNF at 100 ng/ml, caused a change in Ic -2.3 +
1.2 [tA/cm2, n 3, not significantly different to zero)
in rabbit distal colon (data not shown).
Discussion
Cytokines such as IL-1, possess a broad spectrum
of biological activity. They are now being recognized
as essential mediators of both normal and pathologi-
cal immune responses such as temperature regula-
tion, bone and cartilage remodelling, and regulation
of extracellular matrix products. However, increased
levels of these cytokines can.lead to predominance
of proinflammatory effects that characterize disease
states such as sepsis and inflammatory bowel dis-
ease, and to the generation of inflammatory media-
tors such as leukotriene B or PGEs. 19 In this study it
is reported that IL-1[ stimulates ion secretion through
a mechanism which involves the production ofPGE2.
The increase in PGE production observed in this
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FIG. 6. Levels of IL-1 induced-production of PGE in the presence of
cycloheximide (100 lg/ml) (A) compared with a time control (0). Each
point represents mean +/- S.E., n 3.Regulation of ion transport by IL-I
study is consistent with the in vivo experiments
reported by Cominelli et al.2 In the latter report, it
was shown that in the isolated rabbit distal colon a
10 h infusion of IL-1 progressively increases produc-
tion of PGE2, 6-keto PGFla and thromobxane B2. In
the present study it was found that the effect of IL-
l on Isc and on PGE production were not only
concentration- and time-dependent but required pro-
tein synthesis. IL-113 caused an increase in Isc mainly
by increasing Cl- secretion significantly with no effect
on Na ion movement through the apical Na chan-
nel. In pancreatic islet cells, IL-1 was shown to
activate the Na//H exchanger and cause a rapid
increase in cytosolic Na concentration. 21 Since there
is no evidence for the presence of the Na//H ex-
changer in rabbit distal colon, the only possible
explanation for the increased Isc is an increase in C1-
secretion.
Most of the effects of IL-113 on Isc and PGE2 produc-
tion were found to be through protein synthesis.
Induction of protein synthesis in response to IL-1
treatment has been reported in a variety of cells. 22-25
In these studies, alterations in phospholipid metabo-
lism were observed. These were primarily due to
increased PLA2 activity which occurred in response to
IL-1 and which was attributed to induced synthesis
of a phospholipase A activating protein.
26 In human
umbilical vein endothelial cells, IL-1 has recently
been shown to induce cyclooxygenase-2 expression
through a post-transcriptional regulation.
27 In insulin-
secreting cells IL-1 modulates the expression of spe-
cific proteins, not yet identified, but might represent
heat shock protein, superoxide dismutase, or other
proteins involved in the functional response of the
islet to oxidative stress and free radical formation. 28
Although the cell surface receptor for IL-1 has been
cloned,29 it is still largely unknown how it transmits
information to the inside of the cell after IL-1 binding.
The intracellular signals induced by IL-1 appear to be
complex because IL-1 seems to use multiple signal
transduction pathways. 14,15 In the beta cell, for exam-
ple, nitric oxide (NO) has been implicated as the
effector molecule responsible for some of the effects
of IL-1 on cell function. NG-monomethyl-L-arginine
(NM.MA) and NAME, both of which are competitive
inhibitors of nitric oxide synthase, prevent the inhibi-
tory effects of IL-I[ on glucose-stimulated insulin
secretion by isolated islets.3 In our study, however,
using a NOS inhibitor, we found no evidence for NO
being a mediator for IL-1 action.
More than one second messenger seems to be
involved in mediating the effects of IL-1. In different
cell types, such as islets, pituitary, mesangial cells,
chondrocytes and fibroblasts, different mediators
have been described in association with cytokine
action. Some of these mediators included Ca2/,
inositol phosphates, cAMP, protein kinase A, PLC
and PLA as well as alteration in gene transcrip-
tion. 24,31-36 In the intestine, the second messenger(s)
involved in mediating the effect(s) of IL-1 is yet to be
determined.
The human intestinal mucosa has been shown to
be a rich source of IL-1 under normal conditions and
that production of both forms, IL-lot and IL-l[3, is
dramatically increased during pathological condi-
tions such as inflammation. IL-1 has been found to
originate from mononuclear cells in the lamina
propria but not from epithelial cells in normal or
inflamed mucosa. Whether the receptor for IL-1 is
present on epithelial cells, or not, is not yet known,
although some evidence has emerged that IL-113 and
IL-6 receptors have been identified on human
epithelial cells suggesting that these cells can be
regulated directly by proinflammatory cytokines. 37
In conclusion, this study demonstrates that IL-1 has
profound effects on the secretory function of the
normal distal colon. Since IL-1 is significantly in-
creased in inflammatory bowel disease, an under-
standin’g of its mechanism of action on electrolyte
transport in the colon will lead to greater insights into
the pathophysiology of inflammatory bowel disease
and possibly new therapeutic modalities.
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